ID: MRFR/HC/5250-HCR | 110 Pages | Published By Kinjoll Dey on March 2023
The Hemiplegic Migraine Market is expected to reach USD 1.69 Billion by 2030 at 2.90% CAGR during the forecast period 2022-2030. Hemiplegic migraine, although a rare type of migraine its symptoms are almost same as other migraines. Intense and throbbing pain, nausea, and sensitivity to light and sound are some of the symptoms caused by hemiplegic migraine. “Hemiplegia” means paralysis and people suffering from it literally feel temporary symptoms of paralysis such as temporary weakness, numbness and tingling, and paralysis on one side of the body which start before the headache.
Although the hemiplegic migraine is considered as a rare disorder affecting a small number of people, over the past few years, the prevalence of hemiplegic migraine has been increasing. Out of the two types of hemiplegic migraine, familial hemiplegic migraine (FHM) is a hereditary condition that affects at least two close relatives in the same family.
Whereas, the other type, sporadic hemiplegic migraine (SHM) can affect anyone even those who don’t have any family history of the condition. Factors such as changing lifestyle, environmental changes, pollutions, etc. are causes behind the occurrence of SHM. As a result, sporadic hemiplegic migraine is more prevalent than FHM.
However, there are a number of treatment methods available to treat both the types of hemiplegic migraines owing to the technological advancements that happened in the field of medical science in the recent years. Growing prevalence and the availability of treatments are the two key driving forces behind the hemiplegic migraine market growth of hemiplegic migraines.
Considering all these factors, the hemiplegic migraine market is expected to reach approximately 1008 MN USD by the end of 2023, growing at a CAGR of approximately 3.3% during the forecast period (2022-2030). In 2017, the hemiplegic migraine market had valued at USD 830 Million.
The hemiplegic migraine market has been segmented on the basis of type, treatment, preventive treatment, distribution channel, end-user, and region. By type, the hemiplegic migraine market is segmented into familial hemiplegic migraine and sporadic hemiplegic migraine. By end-user, the hemiplegic migraine market is segmented into hospitals & clinics, diagnostic centers, and others.
By treatment, the hemiplegic migraine market is segmented into acute treatment, triptans, ergotamines, nsaids, antiemetics, narcotic analgesics, and others. By preventive treatment, the hemiplegic migraine market is segmented into antidepressants, botox injections, and others. By distribution channel, the hemiplegic migraine market is segmented into retail pharmacies, hospital pharmacies, online pharmacies, and others. By region, the hemiplegic migraine market is segmented into the Americas, Europe, Asia Pacific, and the Middle East & Africa.
The Americas accounts for the leading market due to the higher health care expenditures. The fastest uptake of new technologies in the growing healthcare sector is a major driving force driving the hemiplegic migraine market. The presence of well-established market players is fuelling the market.
The market in the European region stands at the second position in terms of the market size owing to the well-established healthcare sector. Also, high per capita healthcare expenditures play a vital role in the hemiplegic migraine market growth.
Whereas, the Asia Pacific region is expected to grow rapidly due to the emerging economies such as China and India.
In Gulf nations, particularly, Saudi Arabia and UAE drive the Middle Eastern & African market. The African region is estimated to witness moderate growth owing to poor economic & political conditions and inadequate healthcare facilities.
Some of the market leaders profiled in the report are Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Eli Lily and Company, Johnson & Johnson, and Merck & Co.
The research report - Hemiplegic Migraine Market by Market Research Future comprises an in-depth primary research and the detailed analysis of qualitative as well as quantitative aspects of various industry experts. The detailed market analysis gives a clear picture of the current market scenarios including past and future market size in terms of value as well as volume alongside the technological advancement, macroeconomy, and governing factors of the market. The report provides detailed information and strategies of topnotch players in the market while providing a broad study of the market and its various segments in the outlined regions.
Hemiplegic Migraine Market by Type
Hemiplegic Migraine Market by Treatment
Hemiplegic Migraine Market by End-user
Hemiplegic Migraine Market by Preventive Treatment
Hemiplegic Migraine Market by Distribution Channel
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Basis of type, Treatment, Preventive Treatment, Distribution channel, End-user|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Eli Lily and Company, Johnson & Johnson, and Merck & Co|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
Hemiplegic migraine market projected to grow at a 2.90% CAGR between 2022-2030.
Hemiplegic migraine market is predicted to touch USD 1.69 Billion by 2030.
The Americas is expected to lead the hemiplegic migraine market.
Environmental changes and rising prevalence of hemiplegic migraine are the key factors driving the hemiplegic migraine market.
Side effects may limit the hemiplegic migraine market.